ICCM
IceCure Medical Ltd
ICCM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
ICCM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ICCM's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ICCM PE Valuation
ICCM has no meaningful PE right now: it lost money over the past year.
ICCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ICCM's losses to shrink, with revenue growing.
ICCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.76 | +$1.62 |
| Q1 2026 | -$7.02 | +$1.52 |
| Q4 2025 | -$7.15 | +$1.79 |
| Q3 2025 | -$7.82 | +$0.77 |
| Q2 2025 | -$8.38 | +$0.47 |
| Q1 2025 | -$8.54 | +$0.99 |
| Q4 2024 | -$8.94 | +$0.67 |
| Q3 2024 | -$8.59 | +$2.25 |
ICCM is still losing money, but far less than before: $6.76 per share over the past year, against $14.07 at its worst in late 2022.
ICCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $907K | +73% |
| Q1 2026 | $911K | +26% |
| Q4 2025 | $1.3M | +46% |
| Q3 2025 | $850K | +28% |
| Q2 2025 | $525K | -48% |
| Q1 2025 | $725K | -2.4% |
| Q4 2024 | $875K | -30% |
| Q3 2024 | $662K | +102% |
ICCM's revenue is recovering but still below its 2021 peak: $907,000 last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 488% | +1133 points |
| Q1 2026 | -466% | +38 points |
| Q4 2025 | -330% | +188 points |
| Q3 2025 | -2108% | -1460 points |
| Q2 2025 | -645% | -326 points |
| Q1 2025 | -504% | -13 points |
| Q4 2024 | -517% | -245 points |
| Q3 2024 | -648% | +612 points |
ICCM's operating margin was 488% last quarter, up 1133 points from the same quarter a year ago, near the top of its range since 2019.
ICCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | -$1.1M |
| Q1 2026 | -$4.3M | -$277K |
| Q4 2025 | -$5.5M | -$1.3M |
| Q3 2025 | -$2.7M | +$477K |
| Q2 2025 | -$2.8M | -$464K |
| Q1 2025 | -$4M | -$1.2M |
| Q4 2024 | -$4.2M | -$1.6M |
| Q3 2024 | -$3.2M | +$209K |
ICCM has burned cash in almost every quarter: −$16M over the past year, against −$14M the year before.
ICCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +634K shares |
| 1 year | +58% | +1.1M shares |
| 3 years | +103% | +1.6M shares |
| 5 years | +223% | +2.1M shares |
| Available history | +554% | +2.6M shares |
ICCM has 3M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ICCM hasn't bought back shares in the past year.
ICCM Net Leverage
ICCM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ICCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.3 | Oversold |
| Stochastic | 1.5 | Oversold |
ICCM's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
ICCM PE vs Healthcare Sector
ICCM has no meaningful PE right now: it lost money over the past year.
ICCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 36% below |
| 20 week MA | $2.23 | 69% below |
| 50 week MA | $9.11 | 92% below |
| 100 week MA | $20.4 | 97% below |
| 200 week MA | $25.3 | 97% below |
ICCM is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
ICCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $331.5 | $85.2 | -74% |
| 2022 | $85.2 | $42.0 | -51% |
| 2023 | $42.0 | $32.1 | -24% |
| 2024 | $32.1 | $33.6 | +4.7% |
| 2025 | $33.6 | $19.9 | -41% |
| 2026 YTD | $19.9 | $0.70 | -96% |
ICCM has finished lower in four of the last five years. It's down 96% so far in 2026.